非小细胞肺癌寡转移的立体定向放射治疗研究

doi:10.11904/j.issn.1002-3070.2018.02.013

摘要/Abstract

摘要： 非小细胞肺癌(Non-small cell lung cancer,NSCLC)是除小细胞肺癌以外所有类型的肺癌,脑、骨、肝及肾上腺为最常见的远处转移部位。在NSCLC远处转移患者中,并非都是多发的、广泛的,有近7%的患者表现为肺外孤立性转移。这种特殊形式的晚期肿瘤转移状态称之为NSCLC寡转移。寡转移的治疗以局部治疗为主,局部治疗主要措施包括立体定向放疗、手术切除、射频消融等。本文主要探讨立体定向放射治疗(Stereotactic radiotherapy,SRT)对NSCLC在常见远处转移脏器寡转移的作用。

关键词: 非小细胞肺癌, 寡转移, 立体定向放射治疗

Abstract: Non-small cell lung cancer(NSCLC)is the most common type of distant metastasis in all types of lung cancer except for SCLC,including brain,bone,liver and adrenal gland.Of the patients with distant metastases in NSCLC,not all cases are multiple and extensive,with nearly 7% of patients presenting with isolated extrapulmonary metastases.This particular form of advanced tumor metastasis is called NSCLC oligometastatic.Treatment of oligometastatic is mainly local treatment,which includes stereotactic radiotherapy(STR),surgical resection and radiofrequency ablation.The aim of this article is to discuss the effect of SRT on the micrometastasis of common distant metastatic organs in NSCLC.

Key words: Non-small cell lung cancer, Oligodendrocyte metastasis, Stereotactic radiotherapy

中图分类号:

R730.55

杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.

DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.

参考文献

1 Luketich JD,Martini N,Ginsberg RJ,et al.Successful treatment of solitary extraeranial metastases from non-small cell lung cancer[J].Ann Thorac Surg,1995,60(6):1609-1611.
2 Weichselbaum RR,Hellman S.Oligometastases revisited[J].Nat Rev Clin Oncol,2011,8(6):378-382.
3 Yamashita H,Niibe Y,Yamamato T,et al.Lung stereotactic radiotherapy for oligometastases:comparison of oligo-recurrence and sync-oligometastases[J].Jpn J Clinl Oncol,2016,46(7):687-691.
4 Salah S,Tanvetyanon T,Abbasi S.Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases systematic review analysis of reported cases[J].Lung Cancer,2012,75(1):9-14.
5 Juan O,Popat S.Ablative therapy for oligometastatic non-small cell lung cancer[J].Clin Lung Cancer,2017,18(6):595-606.
6 Kennedy TAC,Corkum MT,Louie AV.Stereotactic radiotherapy in oligometastatic cancer[J].Chin Clin Oncol,2017,6(Suppl 2):16.
7 Inoue T,Katoh N.Aoyama H,et al.Clinical outcomes of stereotacticbrain and body radiotherapy or patients with oligometastatic lesions[J].Jpn J Clin Oncol,2010,48(8):788-794.
8 Bai H,Xu J,Yang H,et al.Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy[J].Onco Targets Ther,2016,11(9):4207-4013.
9 Miyazawa K,Shikama N,Okazaki S,et al.Predicting prognosis of short survival time after palliative whole-brain radiotherapy[J].J Radiat Res,2017,24(10):1-7.
10 Pessina F,Navarria P,Cozzi LT,et al.Outcome appraisal of patients with limited brain metastases(BMs)from non small cell lung cancer(NSCLC)treated with different local therapeutic strategies:a single institute evaluation[J].Br J Radiol[J].2017,90(1072):1259-1273.
11 Soliman H,Das S,Larson DA,et al.Stereotactic radiosurgery(SRS)in the modern management of patients with brain metastases[J].Oncotarget,2016,7(11):12318-12330.
12 Zabel SM,Thilmnn C,Zuna I,et al.Treatment of brain metastases in patients with non-small cell lung cancer by stereotactic linac-based radiosurgery:prognostic factors[J].Lung Cancer,2002,37(1):87-94.
13 Schuttrumpf LH,Niyazi M,Nachbichler SB,et al.Prognostic factors for survival and radioation necorsis after stereotactic radiosurgery alone or in combination with whole brain radioation therapy for 1-3 cerebral metastases[J].Radiat Oncol,2014,9(2):1748-1755.
14 Kaul D,Angelidis A,Budach V,et al.Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer[J].Radiat Oncol,2015,10(2):1186-1199.
15 Nibe Y,Nishimura T,Inoue T,et al.Oligo-recurrent predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy:a multi-institutional study of 61 subjects[J].BMC Cancer,2016,16(1):659-667.
16 Miller DA,Krasna MJ.Local therapy indications in the management of patients with oligometastatic non-small cell lung cancer[J].Surg Oncol Clin N Am,2016,25(3):611-620.
17 Minniti G,Salvati M,Muni R,et al.Stereotacticradio surgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer[J].A nticancer Res,2010,30(7):3055-3061.
18 Balducci M,Autorino R,Chiesa S,et al.Radiosurgery plus whole brain radiotherapy in brain oligometastases:a long term analysis[J].Anticancer Res,2015,35(5):3055-3059.
19 Kougioumtzopoulou A,Zygogianni A,Liakouli Z,et al.The role of radiotherapy in bone metastases:A critical review of current literature[J].Eur J Cancer Care(Engl),2017,5(1):181-205.
20 Tseng CL,Eppinga W,Charest-Morin R,et al.Spinestereotactic body radiotherapy:indications,outcomes,and points of caution[J].Global Spine J,2017,7(2):179-197.
21 Bhattacharya IS,Hoskin PJ.Stereotactic body radiotherapy for spinal and bone metastases[J].Clin Oncol,2015,27(5):298-306.
22 Napieralska A,Miszczyk L,Stapor-Fudzinska M.Cyber knife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases[J].Neoplasma,2016,63(2):304-312.
23 Adebahr S,Collette S,Shash E,et al.Lung Tech,an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours:a clinical perspective[J].Br J Radiol,2015,88(3):383-387.
24 Wild AT,Yamada Y.Stereotactic body radiation therapy focus on colorectal cancer[J].Visc Med,2017,33(1):54-61.
25 McGinn CJ,Ten Haken RK,Endminger WD,et al.Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model[J].J Clin Oncol,1998,16(6):2246-2252.
26 Lanciano R,Lamond J,Yang J,et al.Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors[J].Int J Radiat Oncol Bio Phys,2012,10(2):23-36.
27 Goodman BD,Mannina EM,Althouse SK,et al.Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases[J].Pract Radiat Oncol,2016,6(2):86-95.
28 Rule W,Timmerman R,Tong L,et al.Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases[J].Ann Surg Oncol,2011,18(4):1081-1087.
29 Rusthoven KE,Kavanagh BD,Cardenes H.et al.Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases[J].Clin Oncol,2009,27(10):1572-1578.
30 Berkovic P,Gulyban A,Nguyen PV,et al.Stereotactic robotic body radiotherapy for patients with unresectable hepatic oligorecurrence[J].Clin Colorectal Cancer,2017,21(3):1533-1550.
31 Ippolito E,D'Angelillo RM,Fiore M,et al.SBRT:A viable option for treating adrenal gland metastases[J].Rep Pract Oncol Radiother,2015,20(6):484-490.
32 Milano MT,Katz AW,Zhang H,et al.Oligometastases treated with stereotactic body radiotherapy:a long term follow-up of prospective study[J].Int J Radiat Oncol Biol Phys,2012,83(3):878-886.
33 Casamassima F,Livi L,Masciullo S,et al.Stereotactic radiotherapy for adrenal gland metastases:university of florence experience[J].Int J Radiat Oncolbiol Phys,2012,82(2):919-923.
34 Rudra S,Malik R,Ranck MC,et al.Stereotactic body radiation therapy for curative treatment of adrenal metastases[J].Technol Cancer Res Treat,2013,12(3):217-224.

[1]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[2]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[3]	蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.
[4]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[5]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[6]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[7]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.
[8]	代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.
[9]	胡海峰, 冯谢敏, 乔健, 段伟, 刘宁宁, 孙晓东. miR-345在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2017, 31(2): 117-122.
[10]	陈子印, 钱茂森, 潘慧莹. 非共面野在早期非小细胞肺癌立体定向放射治疗方面的剂量学优势[J]. 实用肿瘤学杂志, 2017, 31(2): 142-146.
[11]	张锐，王智煜，王帅，赵晖. 重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 527-522.
[12]	任凤海,王丹丹,王俊峰,徐海,徐世东. 单孔与单操作孔电视辅助胸腔镜手术治疗ⅠA期非小细胞肺癌的临床对比研究[J]. 实用肿瘤学杂志, 2016, 30(4): 327-331.
[13]	叶磊光, 闫安, 刘宝刚. Aurora-A参与非小细胞肺癌化疗药耐药与患者预后的关系[J]. 实用肿瘤学杂志, 2016, 30(2): 97-102.
[14]	陈明慧, 陈喜杰综述, 王艳审校. CD44v6与非小细胞肺癌的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 172-175.
[15]	成龙, 周建国, 周航. 培美曲塞维持治疗晚期非小细胞肺癌临床疗效的Meta分析[J]. 实用肿瘤学杂志, 2016, 30(1): 28-35.